Mettler-Toledo International, Inc. R&D decreased by 2.5% to $51.28M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.6%, from $46.35M to $51.28M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 4.1% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $42.60M | $42.28M | $45.62M | $43.03M | $44.02M | $44.13M | $45.94M | $45.48M | $47.25M | $46.13M | $46.44M | $46.42M | $45.77M | $47.12M | $50.05M | $46.35M | $49.29M | $51.14M | $52.60M | $51.28M |
| QoQ Change | — | -0.8% | +7.9% | -5.7% | +2.3% | +0.2% | +4.1% | -1.0% | +3.9% | -2.4% | +0.7% | -0.0% | -1.4% | +2.9% | +6.2% | -7.4% | +6.3% | +3.8% | +2.8% | -2.5% |
| YoY Change | — | — | — | — | +3.3% | +4.4% | +0.7% | +5.7% | +7.3% | +4.5% | +1.1% | +2.1% | -3.1% | +2.1% | +7.8% | -0.1% | +7.7% | +8.5% | +5.1% | +10.6% |